ICON Selected by Shire as Global Strategic Partner for Clinical Research and Central Laboratory Services
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries, announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.
As a partner for clinical development, ICON will provide Shire with a full range of services including site and country feasibility, ethics, and regulatory submissions, clinical trial monitoring, project management, site, and study team support, medical management, and medical data review. Shire will also utilise ICON Central Laboratories’ extensive test menu from its global network of laboratories.
“We are proud that Shire Specialty Pharmaceuticals has selected ICON as a global partner and it is another endorsement of ICON’s expertise in operating under strategic partnership models,” commented Ciaran Murray, CEO, ICON plc. “ICON’s success is based on the right blend of development services and global testing facilities.. We look forward to building on our successful relationship with Shire to help them realize efficiencies as they seek to bring new products to market.”
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
